Table 5. Cox proportional hazard ratios for mortality in NHL patients.
| Variables | Mortality | Mortality (Adjusted) | ||
|---|---|---|---|---|
| HR [95% CI] | P-value | HR [95% CI] | P-value | |
| Gender (male vs. female) | 1.59 [0.88–2.89] | 0.120 | ||
| Age | 1.03 [1.01–1.05] | 0.013* | 1.03 [1.01–1.06] | 0.005* |
| Stage (III and IV vs. I and II) | 3.86 [1.64–9.09] | 0.002* | 4.21 [1.78–9.95] | 0.001* |
| Rituximab use | 0.65 [0.34–1.22] | 0.179 | ||
| HBsAg positive | 0.69 [0.36–1.32] | 0.260 | ||
| HBV reactivation | 0.82 [0.20–3.38] | 0.779 | ||
| HBV-related hepatitis flare | 0.92 [0.22–3.82] | 0.908 | ||
Notes:
CI, confidence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma.
*
P < 0.05.